Astrazeneca Ab

Proteostasis Therapeutics, Inc.

Entasis Therapeutics, Inc.

Sheila Irene Hauck

Fei Zhou

Gregory Steven Basarab

Madhusudhan Reddy Gowravaram

Michael Barry Gravestock

Matthew Cullen

Markus Haeberlein

Megan Foley

Benito Munoz

Cecilia M Bastos

Bradley Tait

Neil James Hales

Bolin Geng

Kenneth Gregory Hull

George Byron Mullen

Oluyinka Morenike Green

Haihong Ni

Neil James Hale

Kevin Barvian

Stuart D Mills

Brian A Sherer

Michael Lingard Swain

David Timms

Paul Robert Fleming

Pamela Hill

Alexander Louis Breeze

Brian Dangel

Greg Basarab

The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

Proteasome activity enhancing compounds

The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed. 

Compounds and methods for treating bacterial infections

The present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.

Chemical compounds 542

The present invention relates to compounds of Formula (I); to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation. 

Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. 

Antibacterial piperdine derivatives

Compounds of Formula (1) and their pharmaceutically acceptable salts are described: Formula (1) Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. 

Pyrrol derivatives with antibacterial activity

Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, and compounds as shown in (I) wherein C is for example wherein A and B are independently selected from Ra to Rb are independently selected from hydrogen and fluorine;Ra and Rb are independently selected from, for example, hydroxy, &#x2014;NHC(&#x2550;W)R, wherein W is O or S; Ris, for example, hydrogen, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsaturated heterocyclic ring; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

Oxazolidinone and/or isoxazoline as antibacterial agents

Compounds of the formula (I), or a pharmaceutically-acceptable salts, or in-vivo-hydrolysable esters thereo Formula (I): wherein N-HeT is for example triazolyl; Q is for example phenyl or pyridyl, substituted with: T is for example selected from (TAa1 to TAa12) such as (TAa1) and (TAa5): R, R, Rare for example selected from hydrogen, (1&#x2013;4C)alkyl, (1&#x2013;4C)alkoxy-carbonyl, (1&#x2013;4C)alkanoyl and carbamoyl; processes for making them, compositions containing them and their use as antibacterial agents are described.

Antibacterial oxalidinones

Compounds of the formula (I), or a pharmaceutically-acceptable salts, or in-vivo-hydrolysable esters thereof, wherein: N&#x2014;HET is for example triazolyl substituted with R; Ris for example optionally substituted (1-4C)alkyl; Q is for example phenyl or pyridyl, substituted with T; T is for example selected from (TAa1 to TAa12) such as (TAa1 and TAa5); formula (II): R, R, Rare for example selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, (1-4C)alkanoyl and carbamoyl; processes for making them, compositions containing them and their use as antibacterial agents are described.

Antibacterial 1,3-oxazolidin-2-one derivatives

Growing community of inventors

Waltham, MA, United States of America

Sheila Irene Hauck